# Phase 1/2 Biliary Tract cancer trials recruiting: 23 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 23 trials in phase 1/2 for Biliary Tract cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 Biliary Tract cancer trials: 23 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/biliary-tract-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 23
- Recruiting or not yet: 23
- Read on: November 19, 2026

## Trials

The 23 newest of 23, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 2, 2026 | NCT07909031 | CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors | Crescent Biopharma, Inc. | Phase 1/2 | Recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC)... | 219 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909031) |
| June 11, 2026 | NCT07641036 | Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer | Beijing Biotech | Phase 1/2 | Recruiting | Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma, Biliary... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07641036) |
| June 9, 2026 | NCT07636798 | Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer | West China Hospital | Phase 1/2 | Recruiting | Biliary Tract Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07636798) |
| May 28, 2026 | NCT07610798 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced... | Shenzhen Ionova Life Sciences Co., Ltd. | Phase 1/2 | Recruiting | Advance Solid Tumors, Colon and Rectal Cancer, Non - Small Cell Lung Cancer NSCLC, Pancreatic Adenocarcinoma Advanced... | 178 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07610798) |
| December 8, 2025 | NCT07269158 | A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract... | Yonsei University | Phase 1/2 | Not yet recruiting | Biliary Tract Neoplasms, Advanced Cancer, Immunotherapy | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07269158) |
| June 26, 2025 | NCT07038343 | AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors... | Avenzo Therapeutics, Inc. | Phase 1/2 | Recruiting | Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers, Epithelial Tumor, Biliary Tract Cancer... | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07038343) |
| June 13, 2025 | NCT07020221 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | Verastem, Inc. | Phase 1/2 | Recruiting | Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS | 616 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07020221) |
| May 16, 2025 | NCT06975410 | Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors | Yuhan Corporation | Phase 1/2 | Recruiting | EGFR Overexpression, Locally Advanced Solid Tumor, Metastatic Solid Tumor | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06975410) |
| April 24, 2025 | NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | Tanabe Pharma America, Inc. | Phase 1/2 | Recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06943521) |
| April 22, 2025 | NCT06938321 | A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer | Akeso | Phase 1/2 | Recruiting | Biliary Tract Cancer | 135 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06938321) |
| February 11, 2025 | NCT06819215 | Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | Phase 1/2 | Recruiting | Cancer, Neoplasms, Neoplasms, Breast, Tumor, PARP, Ovarian Neoplasms, Prostatic Cancer, Pancreatic Cancer, Breast... | 188 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06819215) |
| November 27, 2024 | NCT06708663 | HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours | Hangzhou Hanx Biopharmaceuticals, Ltd. | Phase 1/2 | Recruiting | Biliary Tract Cancer, Melanoma | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06708663) |
| August 12, 2024 | NCT06548412 | CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers | M.D. Anderson Cancer Center | Phase 1/2 | Recruiting | Metastatic Biliary Tract Cancer | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06548412) |
| May 28, 2024 | NCT06431490 | A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Biliary Tract Cancer | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06431490) |
| May 24, 2024 | NCT06428409 | A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) | Merck Sharp & Dohme LLC | Phase 1/2 | Recruiting | Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06428409) |
| March 26, 2024 | NCT06330064 | A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors... | Daiichi Sankyo | Phase 1/2 | Recruiting | Recurrent or Metastatic Solid Tumors | 680 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06330064) |
| February 2, 2024 | NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | ModeX Therapeutics, An OPKO Health Company | Phase 1/2 | Recruiting | Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric... | 330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06239194) |
| May 9, 2023 | NCT05849480 | A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract... | National Cancer Institute (NCI) | Phase 1/2 | Recruiting | Biliary Cancer, Bile Duct Cancer, Cancer of the Bile Duct | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05849480) |
| March 27, 2023 | NCT05784688 | Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors | TiumBio Co., Ltd. | Phase 1/2 | Recruiting | Solid Tumor, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05784688) |
| October 24, 2022 | NCT05592626 | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid... | Marengo Therapeutics, Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus... | 366 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05592626) |
| September 1, 2022 | NCT05523947 | Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor | Yuhan Corporation | Phase 1/2 | Recruiting | HER2-Positive Solid Tumor | 147 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05523947) |
| August 1, 2022 | NCT05482893 | Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With... | Phanes Therapeutics | Phase 1/2 | Recruiting | Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)... | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05482893) |
| December 9, 2021 | NCT05150691 | A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors | DualityBio Inc. | Phase 1/2 | Recruiting | HER2-positive Advanced Solid Tumor | 796 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05150691) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Yuhan Corporation](https://specstream.ai/data/clinical-trials/company/yuhan-corporation) | 2 |
| Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | 1 |
| DualityBio Inc. | 1 |
| Phanes Therapeutics | 1 |
| [Akeso](https://specstream.ai/data/clinical-trials/company/akeso) | 1 |
| [Beijing Biotech](https://specstream.ai/data/clinical-trials/company/beijing-biotech) | 1 |
| West China Hospital | 1 |
| National Cancer Institute (NCI) | 1 |
| ModeX Therapeutics, An OPKO Health Company | 1 |
| Avenzo Therapeutics, Inc. | 1 |
| M.D. Anderson Cancer Center | 1 |
| Marengo Therapeutics, Inc. | 1 |
| Shenzhen Ionova Life Sciences Co., Ltd. | 1 |
| [Tanabe Pharma America, Inc.](https://specstream.ai/data/clinical-trials/company/tanabe-pharma-america-inc) | 1 |
| Yonsei University | 1 |
| [Verastem, Inc.](https://specstream.ai/data/clinical-trials/company/verastem-inc) | 1 |
| Hangzhou Hanx Biopharmaceuticals, Ltd. | 1 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 1 |
| [Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/chia-tai-tianqing-pharmaceutical-group-nanjing-shunxin-pharmaceutical) | 1 |
| TiumBio Co., Ltd. | 1 |
| Crescent Biopharma, Inc. | 1 |
| [Daiichi Sankyo](https://specstream.ai/data/clinical-trials/company/daiichi-sankyo) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 14 |
| China | 10 |
| South Korea | 6 |
| Australia | 5 |
| Spain | 4 |
| Taiwan | 3 |
| France | 3 |
| Japan | 3 |
| Canada | 2 |
| Chile | 2 |
| Italy | 2 |
| Turkey (Türkiye) | 2 |
| Puerto Rico | 1 |
| Switzerland | 1 |
| United Kingdom | 1 |
| Argentina | 1 |
| Belgium | 1 |
| Brazil | 1 |
| Germany | 1 |
| Ireland | 1 |
| Mexico | 1 |
| Netherlands | 1 |
| Poland | 1 |
| Portugal | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Stone suppliers in the United States](https://specstream.ai/data/businesses/stone-suppliers/united-states)
- [Greek restaurants in the United States](https://specstream.ai/data/businesses/greek-restaurants/united-states)
- [Workers compensation law firms in the United States](https://specstream.ai/data/businesses/workers-compensation-law-firms/united-states)
- [Lighting fixture manufacturers in the United States](https://specstream.ai/data/businesses/lighting-fixture-manufacturers/united-states)
- [Bed and breakfasts in the United States](https://specstream.ai/data/businesses/bed-and-breakfasts/united-states)
- [Pediatric gastroenterology practices in the United States](https://specstream.ai/data/businesses/pediatric-gastroenterology-practices/united-states)
